Conference Coverage of CROI 2022: Clinical Impact of New HIV Data*

Listen to expert insights from Fidelia Bernice, PharmD, and Jennifer Cocohoba, PharmD, as they discuss new data presented at CROI 2022, including key findings on investigational options for PrEP, interactions between hormone therapy and PrEP in transgender individuals, impact of anticholinergic drug effects on older PWH, and medication adherence in PWH.

Fidelia Bernice, PharmD Jennifer Cocohoba, PharmD Released: March 15, 2022

Listen to expert insights from Jeffrey Kwong, DNP, MPH, FAANP, FAAN, and Susan LeLacheur, DrPH, PA-C, AAHIVS, as they discuss new data presented at CROI 2022, including key findings on perinatal ART exposure, an investigational formulation for the prevention of pregnancy and HIV, monitoring requirements in LA CAB for PrEP, and myocardial infarction risk in PWH.

Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS Susan LeLacheur, DrPH, PA-C, AAHIVS Released: March 16, 2022

Hear from CCO’s expert faculty members as they present their insights on some of the most clinically relevant new data presented at CROI 2022, including prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.

Daniel R. Kuritzkes, MD David A. Wohl, MD Released: March 3, 2022

Hear from CCO’s expert faculty members as they present their insights on some of the most clinically relevant new data presented at CROI 2022, including prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.

Monica Gandhi, MD, MPH Babafemi Taiwo, MBBS Released: March 7, 2022

Read expert faculty members’ summaries of key HIV studies from CROI 2022, including results from studies of prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.

Monica Gandhi, MD, MPH Daniel R. Kuritzkes, MD Babafemi Taiwo, MBBS David A. Wohl, MD Released: March 2, 2022

Listen to expert insights from Daniel R. Kuritzkes, MD, and David A. Wohl, MD, on some of the most clinically relevant new data presented at CROI 2022, including prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.

Daniel R. Kuritzkes, MD David A. Wohl, MD Released: March 14, 2022

People with HIV are not experiencing the improvement in myocardial infarction risk reduction observed in those without HIV.

David A. Wohl, MD Released: March 16, 2022

Here’s why I think it is important to combine the science and art of medicine to keep patients at the forefront of decision-making for long-acting ART.

Babafemi Taiwo, MBBS Released: March 15, 2022

As shown in studies at CROI 2022 and elsewhere, SARS-CoV-2 diagnostic testing has illuminated gaps in COVID-19 management, highlighting opportunities to address the needs of individuals and the community.

Megan Coffee, MD, PhD (DPhil) Released: June 2, 2022

The data presented at CROI 2022 had particular relevance for the Central and Eastern European regions, where there are significant delays in PrEP for HIV, varied approaches to HIV/HCV coinfection, and a high prevalence of TB.

Milosz Parczewski, MD, PhD Released: March 11, 2022

Self-administered long-acting antiretroviral therapy will empower people with HIV and enhance patient privacy, but there may be trade-offs.

José R. Arribas, MD Released: March 10, 2022

My perspective on how the latest data on long-acting antiretrovirals presented at CROI 2022 will impact HIV prevention and management in Africa.

Jonah Musa, MBBS, MSCI, PhD Released: March 4, 2022

Read my thoughts on the most important papers on HIV cure from the recent CROI 2022 virtual meeting.

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: March 11, 2022

Read my take on promising new data from CROI 2022 on a vaginal ring containing tenofovir and long-acting cabotegravir as PrEP.

Darrell H. S. Tan, MD, FRCPC, PhD Released: March 1, 2022

Here’s my take on the latest data from the VISEND and 2SD studies presented at CROI 2022.

Brenda E. Crabtree Ramírez, MD Released: March 4, 2022

Read my thoughts on new data from the recent CROI 2022 virtual meeting in support of using dolutegravir in second-line HIV therapy.

Yan Zhao, MD Released: March 14, 2022

Découvrez les résumés d’études clés sur le VIH présentés par des professeurs experts lors de la CROI 2022, notamment les résultats d’études sur les stratégies de prévention, les thérapies à action prolongée, les traitements de deuxième intention, les comorbidités et le remède.

Monica Gandhi, MD, MPH Daniel R. Kuritzkes, MD Babafemi Taiwo, MBBS David A. Wohl, MD Released: March 18, 2022

Leia os resumos dos principais estudos de VIH dos membros do corpo docente especialistas do CROI 2022, incluindo resultados de estudos de estratégias de prevenção, terapias de ação prolongada, terapias de segunda linha, comorbidades e cura.

Monica Gandhi, MD, MPH Daniel R. Kuritzkes, MD Babafemi Taiwo, MBBS David A. Wohl, MD Released: March 18, 2022

Lea los resúmenes de un panel de expertos de los estudios clave sobre el VIH de CROI 2022, incluidos los resultados de los estudios de estrategias de prevención, terapias de acción prolongada, tratamientos de segunda línea, comorbilidades y cura.

Monica Gandhi, MD, MPH Daniel R. Kuritzkes, MD Babafemi Taiwo, MBBS David A. Wohl, MD Released: March 18, 2022